PFIZER INC Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment
PFIZER INC (PFE) reported Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment of $59.00 million for the 12-month period ending 2012-12-31, per its 10-K filed 2014-02-28.
Discontinued › Income Statement › Other Income
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments · last filed 2014-02-28
- PFIZER INC defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for the quarter ending 2012-12-31 was $0.00.
- PFIZER INC defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for the quarter ending 2012-09-30 was $0.00.
- PFIZER INC defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for the quarter ending 2012-07-01 was $59.00M.
- PFIZER INC defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for fiscal 2012 was $59.00M.
| Period end | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 3 month | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 6 month | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 9 month | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $0.00 derived: sum of 2 quarters · filed 2014-02-28 | $59.00M derived: sum of 3 quarters · filed 2014-02-28 | $59.00M 10-K · filed 2014-02-28 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $59.00M derived: sum of 2 quarters · filed 2012-11-09 | $59.00M 10-Q · filed 2012-11-09 | |
| 2012-07-01 | $59.00M 10-Q · filed 2012-08-09 | $59.00M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |